We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | EU:SAN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.80 | -0.87% | 90.96 | 90.60 | 91.82 | 91.86 | 90.75 | 91.14 | 1,839,942 | 16:45:55 |
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SAN.FR, SNY) on Tuesday said they plan to restructure their collaboration for Kevzara and Praluent into a royalty-based agreement.
Under the changes, France's Sanofi would gain sole global rights to the rheumatoid-arthritis treatment Kevzara, along with sole rights to the cholesterol drug Praluent outside the U.S.
Regeneron, based in Tarrytown, N.Y., would gain sole U.S. rights to Praluent.
The companies said the move doesn't affect their collaboration relating to the eczema and asthma treatment Dupixent, which Sanofi Chief Executive Paul Hudson on Monday said "has the chance to be one of the most successful medicines in the history of the industry."
Sanofi and Regeneron said each company will be solely responsible for funding development and commercialization expenses in their respective territories under the changes, which they expect to finalize in the first quarter.
Sanofi, which holds a 21.6% stake in Regeneron, on Monday said it would stop investing in research into diabetes and cardiovascular diseases as part of a broader strategic overhaul.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2019 09:07 ET (14:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions